Skip to main content
. 2015 Sep 30;5:14538. doi: 10.1038/srep14538

Figure 9. JAK2-V617F/L983F confers resistance in vivo.

Figure 9

One million BaF3 cells expressing luciferase and a single JAK2-V617F variant were transplanted via tail vein in syngeneic Balb/c mice. After 3 days, mice were injected twice daily with ruxolitinib (100 mg/kg) for two weeks. Leukemic burden were measured by monitoring the bioluminiscence—7 days (left panel) and 14 days (right panel). As expected, JAK2-V617F/L983F conferred resistance, JAK2-V617F and JAK2-V617F/Y931C are responsive to ruxolitinib treatment.